Amneal announced FDA approval of exenatide 5mcg/1.2mL and 10mcg/2.4mL prefilled pen injection on November 21, 2024. This generic references Byetta® (exenatide – AstraZeneca), a glucagon-like peptide-1 (GLP-1) receptor agonist indicated…
The Inflation Reduction Act (IRA) of 2022 created the Medicare Drug Price Negotiation (DPN) Program in an effort to decrease the of cost of medications through Medicare. As a result of this program, the Centers for Medicare & Medicaid Services (CMS), select…
On October 2, 2024, Mylan Pharmaceuticals and Novo Nordisk reached a confidential settlement agreement regarding the launch date of generic versions of Ozempic (semaglutide). Although the agreement remains confidential…
The 2022 Inflation Reduction Act (IRA) makes significant changes to the Medicare Part D standard benefit, including capping annual enrollee out-of-pocket spending. The new provisions are being implemented gradually through 2025. While some changes…
On September 27th, 2024, the FDA approved Sanofi/Regeneron's Dupixent® (dupilumab) for use as an add-on maintenance treatment of adults who have inadequately controlled chronic obstructive pulmonary disease (COPD) and eosinophilic phenotype. In clinical trials,…
